MedTrace Logo

Mesalazine Oral Suspension in Active Eosinophilic Esophagitis

NCT05488405 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2023-09-07

No results posted yet for this study

Summary

Pilot study to assess a mesalazine oral suspension in active eosinophilic esophagitis

Conditions

  • Eosinophilic Esophagitis

Interventions

DRUG

Mesalamine Oral Product

Mesalamine oral suspension for oral use

Sponsors & Collaborators

  • Dr. Falk Pharma GmbH

    lead INDUSTRY

Principal Investigators

  • Luc Biedermann, PD Dr. med. · UniversitätsSpital Zürich Klinik für Gastroenterologie und Hepatologie

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-09
Primary Completion
2023-06-30
Completion
2023-07-20

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05488405 on ClinicalTrials.gov